Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability
- 20 Downloads
To evaluate the prognostic role of BRAF and KRAS mutations after adjustment for microsatellite instability (MSI) in Iranian colorectal cancer (CRC) patients.
BRAF and KRAS mutations and MSI status were assessed in 258 Iranian subjects with CRC. Two hundred fifty-eight consecutive stages I-IV CRC patients, who underwent surgical resection of adenocarcinoma from 2012 to 2016, were enrolled in the research. Pyrosequencing and Cast-PCR methods were used to the detection of KRAS and BRAF mutations. Kaplan-Meier and Cox regression were employed to estimate hazard ratios (HR) for the association between BRAF and KRAS mutation and overall survival (OS).
KRAS and BRAF mutations were detected in 36 (14%) and 15 (5.8%) cases of 258 patients with CRC, respectively. BRAF mutations that all comprised V600E and KRAS mutations was found in codon 12 and 13 (80.6% and 19.4%), respectively. KRAS mutations were detected in 19 (15.4%) patients of 123 microsatellite stable (MSS) CRC and it is significantly associated with tumor location and metastasis. BRAF and KRAS mutant vs. wild type of BRAF and KRAS, 5-year OS was 73.3% vs. 82.3% and 83.3% vs. 81.5% (long-rank P > 0.05), respectively. KRAS mutant vs. KRAS-wild-type tumors in MSS/MSI-L status CRC patients, 5-year OS was 78.9% vs. 90.4% (long-rank p = 0.046).
The present study revealed that BRAF and KRAS mutations were not related to the worse overall survival, while KRAS mutation can be a prognostic factor for overall survival in sporadic microsatellite-stable (MSS) status in Iranian CRC patients.
KeywordsKRAS BRAF Survival Colorectal cancer Prognostic value Iran
This study was performed in Shahid Beheshti University of Medical Sciences and supported by grant number 8910.
This project was completely supported and funded by Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences and Medical Ethical committee of RCGLD with the Ethic NO: IR.SBMU.RIGLD. REG.1391.681.
Compliance with Ethical Standards
The Ethical Committee of the Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, approved this research (IR.SBMU.RIGLD.REC.1396.681).
Conflict of Interest
The authors declare that they have no conflict of interest.
The authors have nothing to disclose.
- 2.Safaei A, Moghimi-Dehkordi B, Fatem SR, Pourhoseingholi MA, Ghiasi S, Zali MR. Colorectal cancer in Iran: an epidemiological study. APJCP. 2008;9(1):123–6.Google Scholar
- 3.Worthley DL, Leggett BA. Colorectal cancer: molecular features and clinical opportunities. Clin Biochem Rev. 2010;31(2):31–8.Google Scholar
- 4.Nazemalhosseini Mojarad E, Kuppen PJ, Aghdaei HA, Zali MR. The CpG island methylator phenotype (CIMP) in colorectal cancer. GHFBB. 2013;6(3):120–8.Google Scholar
- 9.Bronte G, Silvestris N, Castiglia M, Galvano A, Passiglia F, Sortino G, et al. New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS? Oncotarget. 2015;6(28):24780–96. https://doi.org/10.18632/oncotarget.4959.CrossRefGoogle Scholar
- 11.Omidifar NM, Geramizadeh BM, Mirzai MM. K-ras mutation in colorectal Cancer, a report from southern Iran. Iran J Med Sci. 2015;40(5):454–60.Google Scholar
- 12.Molaei M, Kishani Farahani R, Maftouh M, Taleghani MY, Vahdatinia M, Khatami F, et al. Lack of BRAFV600E mutation in stage I and II of colorectal cancer. GHFBB. 2016;9(2):94–9.Google Scholar
- 19.Bishehsari F, Mahdavinia M, Malekzadeh R, Verginelli F, Catalano T, Sotoudeh M, et al. Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. Ann Oncol. 2006;17(Suppl 7):vii91–6. https://doi.org/10.1093/annonc/mdl959.CrossRefGoogle Scholar
- 20.Shemirani AI, Haghighi MM, Milanizadeh S, Taleghani MY, Fatemi SR, Damavand B, et al. The role of kras mutations and MSI status in diagnosis of colorectal cancer. GHFBB. 2011;4(2):70–5.Google Scholar
- 21.Sobhani S, Ghaffarpour M, Mostakhdemin Hosseini Z, Kamali F, Nour Mohammadi Z, Houshmand M (2010) The prevalence of common mutation frequency in K-ras codons 12, 13 in Iranian Colorectal Cancer patients. Genetics in the 3rd Millennium 8:2011–8.Google Scholar
- 23.Payandeh M, Sadeghi M, Sadeghi E, Gholami F. Analysis of KRAS, BRAF and NRAS in Patients with Colorectal Cancer: the First Report of Western Iran. Am J Cancer Prev. 2015;3(1):19–22.Google Scholar
- 24.Koochak A, Rakhshani N, Karbalaie Niya MH, Tameshkel FS, Sohrabi MR, Babaee MR, et al. Mutation analysis of KRAS and BRAF genes in metastatic colorectal Cancer: a first large scale study from Iran. Asian Pac J. Cancer Prev. 2016;17(2):603–8.Google Scholar
- 25.Watanabe T, Yoshino T, Uetake H, Yamazaki K, Ishiguro M, Kurokawa T, et al. KRAS mutational status in Japanese patients with colorectal cancer: results from a nationwide, multicenter, cross-sectional study. Jpn J Clin Oncol. 2013;43(7):706–12. https://doi.org/10.1093/jjco/hyt062.CrossRefGoogle Scholar
- 26.Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28(3):466–74. https://doi.org/10.1200/jco.2009.23.3452.CrossRefGoogle Scholar
- 30.Zulhabri O, Rahman J, Ismail S, Isa MR, Wan Zurinah WN. Predominance of G to a codon 12 mutation K-ras gene in Dukes' B colorectal cancer. Singapore Med. 2012;J53(1):26–31.Google Scholar
- 32.Kleist B, Kempa M, Novy M, Oberkanins C, Xu L, Li G, et al. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer. Int J Clin Exp Pathol. 2014;7(9):5927–39.Google Scholar
- 33.Siyar Ekinci A, Demirci U, Cakmak Oksuzoglu B, Ozturk A, Esbah O, Ozatli T, et al. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma. J Buon. 2015;20(1):128–35.Google Scholar
- 35.Ghaffarpour M, Mohammadi Pargoo E, Sobhani S, Pirmoradi S, Mostakhdemin Hosseini Z, Kamali F, et al. (Cancer Res 2011) PIK3CA and BRAF mutational status and association with clinicopathological features in Iranian colonrectal cancer patients. Cellular and Molecular Biology 71(8 Suppl):Abstract nr 3799.Google Scholar
- 38.De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncology. 2010;11(8):753–62. https://doi.org/10.1016/s1470-2045(10)70130-3.CrossRefGoogle Scholar
- 40.Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer (Oxford, England: 1990). 2015;51(5):587–94. https://doi.org/10.1016/j.ejca.2015.01.054.CrossRefGoogle Scholar
- 41.Nakanishi R, Harada J, Tuul M, Zhao Y, Ando K, Saeki H, et al. Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer. IJCO. 2013;18(6):1042–8.Google Scholar